Related Experiment Video
Updated: Feb 5, 2026

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Published on: December 5, 2017
Targeted agents for HER2-positive breast cancer in older adults: current and future perspectives
Enrique Soto-Perez-De-Celis1, Kah Poh Loh2, Capucine Baldini3
1a Department of Geriatrics , Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran , Mexico City , Mexico.
Introduction:
One-third of breast cancer (BC) cases worldwide occur in women aged 65 years and older, with 10 to 15% overexpressing the human epidermal growth factor receptor 2 (HER2). Although several HER2-targeted therapies have been developed, the lack of data regarding their use in older patients hampers evidence-based decision-making for this population.
Areas Covered:
We review current evidence on the efficacy and safety of HER2-targeted therapies in older adults with BC, focusing on approved therapies such as trastuzumab, lapatinib, pertuzumab, ado-trastuzumab-emtansine, and neratinib. Additionally, we discuss drugs under development to target the HER2-receptor, and to overcome resistance to existing therapies. Finally, we highlight the cardiotoxicity of HER2-targeted drugs among older adults.
Expert Opinion:
Older adults are underrepresented in trials of HER2-targeted therapies in BC. We propose strategies to increase recruitment of older adults in clinical trials in order to increase the evidence base to treat this growing population.
Insights
Older adults with HER2-positive breast cancer (BC) have limited data on targeted therapies. This review examines current HER2 treatments, discusses new drugs, and highlights cardiotoxicity risks in this population.
Area of Science:
- Oncology
- Geriatric Medicine
- Pharmacology
Background:
- Breast cancer (BC) disproportionately affects older women (≥65 years), with 10-15% overexpressing human epidermal growth factor receptor 2 (HER2).
- Existing HER2-targeted therapies lack sufficient data for optimal use in elderly patients, hindering evidence-based treatment decisions.
Purpose of the Study:
- To review the efficacy and safety of approved HER2-targeted therapies in older adults with BC.
- To discuss emerging HER2-targeting drugs and strategies for overcoming treatment resistance.
- To highlight the cardiotoxicity associated with HER2-targeted therapies in the geriatric population.
Main Methods:
- Comprehensive literature review of current evidence on HER2-targeted therapies in older adults with BC.
- Focus on approved agents: trastuzumab, lapatinib, pertuzumab, ado-trastuzumab-emtansine, and neratinib.
- Exploration of novel therapeutic agents and resistance mechanisms.
Main Results:
- Older adults are underrepresented in clinical trials for HER2-targeted BC therapies.
- Cardiotoxicity is a significant concern for HER2-targeted drugs in this demographic.
- Evidence for efficacy and safety in older adults is limited but growing.
Conclusions:
- Increased recruitment of older adults into clinical trials is crucial for generating robust evidence.
- Tailored treatment strategies considering age-related factors and potential toxicities are needed.
- Further research is required to optimize HER2-targeted therapy for elderly patients with breast cancer.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Position-effect Variegation
Psychodynamic Perspectives on Personality
Psychodynamic theorists argue that unconscious...
Criticisms of the Evolutionary Perspective
Evolutionary psychology provides one explanation for these findings, suggesting...
The Behavioral Perspective on Personality
Social Cognitive Perspective on Personality

